- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Parkinsonism-Hyperpyrexia Syndrome: A Differential to Consider in Psychiatric Dysautonomias () - May 2, 2021 - Abstract #APA2021APA_539;
While the patient’s refusal of Carbidopa/Levodopa was more immediately apparent as a potential precipitant to his presentation, his minimal improvement after being resumed on this medication suggests that the deactivation of his DBS device played a more central role in his clinical deterioration. Providers should be aware of the potential for NMS-like presentations – even in patients not receiving neuroleptics – should other factors be in place that may acutely diminish dopaminergic tone.
- |||||||||| APO-go (apomorphine continuous subcutaneous infusion) / Stada, Kyowa Hakko Kirin, Endo, Supernus Pharma, Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie
Clinical, Journal: Continuous and advanced treatment strategies in the old to very old parkinsonian population. (Pubmed Central) - Apr 28, 2021
What is at stake is to aim for the best motor state possible while limiting iatrogenic adverse events. New emerging, potentially less invasive, techniques, such as gamma knife thalamotomy or high-intensity focused ultrasound thalamotomy or sub-thalamotomy, are also discussed here.
- |||||||||| carbidopa/levodopa / Generic mfg.
Preclinical, Journal: Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model. (Pubmed Central) - Apr 27, 2021
Histopathological evaluation showed a high number of eosinophilic lesions in the rotenone group which were found to be very less in the VA co-treated group. The study thus proved that co-treatment of VA and levodopa-carbidopa, significantly protected the brain from neuronal damage due to oxidative stress and attenuated the motor defects indicating the possible therapeutic potential of VA as a neuroprotective in PD.
- |||||||||| [VIRTUAL] The (Anti)Psychotic Paradox: Lewy Body Dementia (e-Poster Gallery) - Apr 26, 2021 - Abstract #EPA2021EPA_518;
According to his wife (principal keeper), it stills a paranoid speech with fluctuant delusional ideas conditioned by visual hallucinations, predominantly in the evening, with no amelioration in four years clozapine treatment, adding a progressive parkinsonism impairment despite neurological drugs (carbidopa:levodopa). Doing a bibliographical review, we found a 2019 article (with 3 Systematic review/Metanalysis and 3 Clinical Practice Guidance, including in NICE), where point olanzapine 5mg well effective but worse tolerated and light up quetiapine as choice that should be considered (no doses specified). Results One month later of therapeutic trial following the review in our clinical case, changing clozapine for quetiapine (50mg / 12h), we found an improvement of motor control and a reduction of psychotic manifestation that allows a less disruptive behavior in our patient, also objectified by his principal keeper. Conclusions While bibliography doesn’t point a specific dose drug guide for antipsychotic treatment in LBD, in our clinical trial we detected a better control of symptoms using low dose quetiapine, nevertheless more studies are needed.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Autosomal dominant GCH1 mutations causing spastic paraplegia at disease onset. (Pubmed Central) - Apr 13, 2021
GCH1 mutations may cause a phenotype initially resembling hereditary spastic paraplegia (HSP) rather than DRD, with basal ganglia signs developing only after decades. In order not to miss this treatable condition, GCH1 should be included in HSP gene panels and its testing is pivotal in patients with spastic paraplegia, especially if there are concomitant basal ganglia signs and/or diurnal fluctuation.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Clinicopathologic Characteristics of Melanoma in Parkinson's Disease Patients () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_700;
Most patients received carbidopa/levodopa for PD (n=60, 85.7%)...Melanoma was preferentially localized to the head/neck region and was most often characterized as melanoma in situ. Further exploration of common markers, affected genes, and mutations could inform future research on an underlying shared disease pathway.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Anticholinergic use and antipsychotic initiation in dementia: an evaluation of prescribing at a Veterans Affairs Medical Center () - Apr 4, 2021 - Abstract #CPNP2021CPNP_154;
Exclusion criteria includes those with schizophrenia or bipolar related disorders, depressive disorders, Parkinson's disease, restless legs syndrome, traumatic brain injury, human immunodeficiency virus, Huntington's disease, Lewy body disease, substance use disorders (except tobacco and marijuana use disorder), use of antipsychotic use on or prior to index date, first antipsychotic use after hospice care initiated, or use of carbidopa/levodopa, benzodiazepines, dopamine agonists, or stimulants...Outcomes: The primary outcome will be to assess the average daily anticholinergic exposure to veterans diagnosed with dementia up to a 10-year period and relative risk of antipsychotic prescribing per anticholinergic exposure score category. Time to antipsychotic prescribing and time to death from index date, as well as acetylcholinesterase inhibitor or memantine prescription at time of antipsychotic prescribing will also be investigated.
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
New trial: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Mar 29, 2021
P, N=40, Recruiting,
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Acute-Onset Parkinsonism Secondary To Bilateral Extrapontine Myelinolysis Of The Basal Ganglia: A Case Report. () - Mar 18, 2021 - Abstract #AAN2021AAN_1455;
ODS can occur with slow rates of sodium correction, but the most common manifestation is a flaccid quadriparesis; rarely, ODS can manifest with acute-onset parkinsonism. Following an initial stage of diffuse encephalopathy, the neurological sequelae are usually of diffuse cognitive deficits and extrapyramidal or corticobulbospinal disorders; however, the patient was definitively asymptomatic after short therapy with low-dose levodopa-carbidopa.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model () - Mar 18, 2021 - Abstract #AAN2021AAN_1413;
Objective: To describe the population pharmacokinetics (PK) of levodopa and carbidopa following subcutaneous (SC) infusion with ND0612, with and without oral therapy, including associated interindividual variability and residual unexplained variability. Model diagnostics for the carbidopa and levodopa population PK models indicated a satisfactory predictive performance, supporting their usability to derive individual predictions of exposure to be used in future pharmacokinetic-pharmacodynamic analyses.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] A case of TUBB4A-related hypomyelinating leukodystrophy with abnormal movements responsive to levodopa/carbidopa () - Mar 18, 2021 - Abstract #AAN2021AAN_1291;
In PD patients with motor fluctuations and reporting troublesome dyskinesia, exposure to opicapone for almost 1 year was associated with reduced levodopa dose, reduced ON-time with troublesome dyskinesia, and increased ON-time with no/non-troublesome dyskinesia. These observations suggest that levodopa/carbidopa may be a therapeutic option for H-ABC patients presenting with extrapyramidal symptoms.
- |||||||||| amantadine / Generic mfg.
[VIRTUAL] A Case of Legionella Associated Rhombo-Cerebellitis. () - Mar 18, 2021 - Abstract #AAN2021AAN_1276;
We discuss a case of persistent ataxia and rubral tremor secondary to legionella associated rhombo-cerebellitis. It is critical to be aware of prolonged neurological manifestations of Legionnaires disease in the absence of imaging findings.
- |||||||||| modafinil / Generic mfg., carbidopa/levodopa / Generic mfg.
Clinical, Journal: Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. (Pubmed Central) - Mar 11, 2021
We present a case of a 60 year old patient who sustained a prolonged hospitalization with COVID-19, had a cerebrovascular event and developed a persistent unexplained encephalopathy along with a hypokinetic state. He was treated successfully with modafinil and carbidopa/levodopa showing clinical improvement within 3-7 days and ultimately was able to successfully discharge home.
- |||||||||| APO-go (apomorphine continuous subcutaneous infusion) / Stada, Kyowa Hakko Kirin, Endo, Supernus Pharma, Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie
Clinical, Journal: Continuous and advanced treatment strategies in old and very old patients with Parkinson's disease. (Pubmed Central) - Mar 10, 2021
What is at stake is to aim for the best motor state possible while limiting iatrogenic adverse events. New emerging, potentially less invasive, techniques, such as gamma knife thalamotomy or high-intensity focused ultrasound thalamotomy or sub-thalamotomy, are also discussed here.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions. (Pubmed Central) - Feb 25, 2021
Current pharmacotherapy of Parkinson's disease (PD) is symptomatic and palliative, with levodopa/carbidopa therapy remaining the prime treatment, and nevertheless, being unable to modulate the progression of the neurodegeneration...Further, gripping preclinical and clinical studies demonstrate the context regarding the cannabinoid compounds, which is supported by various evidence (neuroprotection, suppression of excitotoxicity, oxidative stress, glial activation, and additional benefits) provided by cannabinoid-like compounds (much research addresses the direct regulation of cannabinoids with dopamine transmission and other signalling pathways in PD). More data related to endocannabinoids efficacy, safety, and pharmacokinetic profiles need to be explored, providing better insights into their potential to ameliorate or even regress PD.
- |||||||||| risperidone / Generic mfg.
Clinical, Review, Journal: Drug interactions for elderly people with mental and behavioral disorders: a systematic scoping review. (Pubmed Central) - Feb 23, 2021
More data related to endocannabinoids efficacy, safety, and pharmacokinetic profiles need to be explored, providing better insights into their potential to ameliorate or even regress PD. Knowing the clinical conditions or risk morbidities associated with the use of potentially inappropriate medications and management of these medications for safer therapeutic equivalents or non-pharmacotherapeutic alternatives are relevant for patient safety.
- |||||||||| Enrollment open: Dopaminergic Dysfunction in Late-Life Depression (clinicaltrials.gov) - Feb 16, 2021
P2, N=60, Recruiting,
Knowing the clinical conditions or risk morbidities associated with the use of potentially inappropriate medications and management of these medications for safer therapeutic equivalents or non-pharmacotherapeutic alternatives are relevant for patient safety. Not yet recruiting --> Recruiting
- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, Journal: Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study. (Pubmed Central) - Feb 16, 2021
Greater baseline brain volumes and cortical thickness in regions supporting cognition and gait were associated with higher behavioral performance, while lower structural integrity was associated with increased responsivity to L-DOPA. If substantiated in larger studies, these findings could facilitate the targeting of dopaminergic treatments to those LLD patients most likely to respond.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Orodispersible films as a personalized dosage form for nursing home residents, an exploratory study. (Pubmed Central) - Feb 7, 2021
Most of these active pharmaceutical ingredients have a bitter taste and poor water solubility, which is a challenge for orodispersible film production. Conclusions The most suitable active pharmaceutical ingredient candidates for manufacturing of orodispersible films for the ageing patient population may be the combination of levodopa and carbidopa used to treat the symptoms of Parkinson's disease, and baclofen used to treat spasticity.
- |||||||||| lamivudine HBV / Generic mfg.
[VIRTUAL] Fanconi's Syndrome and Dementia in a Patient With Chronic Hepatitis B Taking Nucleoside/ Nucleotide Analogue (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_919;
Because of LAM resistance, adefovir dipivoxil 10mg qd (ADV) was added in Jul 2007...TDF was then switched to tenofovir alafenamide (TAF) 25mg qd in Mar 2019...He was given Sinemet 25/100 and rivastigmine by neurologist with some improvement...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
- |||||||||| Trial completion date, Trial primary completion date: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) (clinicaltrials.gov) - Jan 28, 2021
P4, N=90, Not yet recruiting,
The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021. Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Mar 2026
- |||||||||| Journal: Levodopa Positively Affects Neovascular Age-related Macular Degeneration. (Pubmed Central) - Jan 26, 2021
Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Mar 2026 Our findings suggest efficacy and support the pharmacological targeting of GPR143 with levodopa for the treatment of nAMD in future studies.
- |||||||||| carbidopa/levodopa / Generic mfg.
PK/PD data, Journal: Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. (Pubmed Central) - Jan 23, 2021
An additional nutritional supplementation with methyl group donating and free radical scavenging vitamins is recommendable, when future drugs are developed for long term levodopa/dopa decarboxylase treated patients. Personalised medicine treatment concepts shall also consider nutritional aspects in Parkinson's disease.
- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, Journal: New Therapeutic Options for the Individualised Titration of Levodopa (Pubmed Central) - Jan 23, 2021
For this reason, the introduction of water-soluble microtablets à 5 / 1.25 mg levodopa / carbidopa can be regarded as a beneficial extension permitting for fine titration of the dopaminergic stimulation. Here we present this new therapeutic principle, the available data and concepts for clinical use.
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Parkinson Disease. (Pubmed Central) - Jan 1, 2021
Motor symptoms are managed with carbidopa/levodopa, monoamine oxidase-B inhibitors, and nonergot dopamine agonists...Nonmotor symptom therapies target patient-specific conditions during the disease course. Interdisciplinary team care can alleviate multiple symptoms of Parkinson disease.
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Dec 11, 2020
P2, N=32, Completed,
Therefore, in PD patients where impaired motor performance develops and the application of entacapone is necessary, it is suggested to be administered in a single tablet form. Recruiting --> Completed | N=52 --> 32 | Trial completion date: Mar 2021 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) - Dec 11, 2020
P2, N=35, Completed,
Recruiting --> Completed | N=52 --> 32 | Trial completion date: Mar 2021 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020 Recruiting --> Completed | N=52 --> 35 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Mar 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Dec 11, 2020
P2, N=21, Completed,
Recruiting --> Completed | N=52 --> 35 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Mar 2020 Recruiting --> Completed | N=52 --> 21 | Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Dec 2020 --> Dec 2019
|
